Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily memantine in moderate to severe Alzheimer's disease
2006-003616-21Phase 3Completed
- Sponsor
- Merz
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of memantine in Alzheimer's disease (AD), sponsored by Merz. Primary endpoint: Mean change in CERAD-NP total score from baseline to week 12. Started Jul 2007; status: completed.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-003616-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003616-21.